GSK Announces Offer to Repurchase Exchangeable Senior Notes Due 2023

For media and investors only

GSK plc (LSE/NYSE: GSK) announced today that its wholly owned subsidiary, GSK Finance (No.3) plc, is offering to repurchase for cash any and all of its outstanding Exchangeable Senior Notes due 2023 (CUSIP No. 36259 RAA0).

Pursuant to the offer, each holder may require the notes’ issuer to repurchase all or part of such holder’s notes at a price equal to 100% of principal amount. Holders may exercise their right to require the repurchase of notes through 5:00 p.m. ET on 16 September, 2022. As of the date of this notice, approximately $280 million aggregate principal amount of the notes is outstanding.

The offer to repurchase is being made on the terms and subject to the conditions set forth in the indenture governing the notes and the notice of offer to repurchase that has been delivered to holders of the notes. This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell the notes or any other securities.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at www.gsk.com/company/

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q2 Results for 2022 and any impacts of the COVID-19 pandemic.